The IPO at the top of the range signals strong institutional demand. The key catalyst is the FDA decision on Oxnimbi by February 28, 2027. Monitor for FDA advisory committee meetings, any clinical data updates, and progress on manufacturing scale-up. The stock will likely trade on binary approval expectations over the next 7 months.
Executive Summary
Apnimed priced its IPO of 12,000,000 shares at $16.00 per share, at the top of the $14-$16 range, raising $192.0 million in gross proceeds ($173.6 million net). The company is a late-stage biopharmaceutical firm with a sole clinical candidate, Oxnimbi (AD109) for obstructive sleep apnea, whose NDA was accepted by the FDA with a PDUFA date of February 28, 2027. The IPO proceeds, combined with existing cash, are expected to fund operations through June 2028, covering the regulatory approval process and potential commercial launch.
Key Financial Metrics
Key Facts
- IPO of 12,000,000 shares priced at $16.00 per share, gross proceeds of $192.0 million
- Net proceeds to company estimated at $173.6 million after underwriting discounts and estimated expenses
- Underwriters have a 30-day option to purchase up to an additional 1,800,000 shares
- PDUFA goal date for Oxnimbi (AD109) NDA is February 28, 2027
- Pro forma as-adjusted cash and cash equivalents of $367.9 million as of March 31, 2026
- Company had an accumulated deficit of $329.6 million as of March 31, 2026 and a going concern uncertainty prior to the offering
- New investors will experience immediate dilution of $8.55 per share (53.4% of offering price)
- Use of proceeds: approximately $237.8 million for regulatory approval and commercial launch of Oxnimbi; remainder for R&D, working capital
Financial Impact
Gross proceeds of $192.0 million ($173.6 million net) extend runway through June 2028, funding the PDUFA catalyst and potential commercial launch. Dilution of 30.1% to existing shareholders.
Risk Factors
- FDA may not approve Oxnimbi due to clinical meaningfulness concerns raised at pre-NDA meeting
- Competition from PAP devices, GLP-1 therapies (tirzepatide), and neurostimulation devices
- Going concern risk if approval is delayed or denied despite IPO proceeds
- Dilution from future equity offerings or exercise of warrants/options
- Side effect profile (insomnia, dry mouth) may limit market adoption if approved
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-328422 |
| Document: 0001193125-26-328422-index-headers.html | 0001193125-26-328422 |
| Document: 0001193125-26-328422-index.html | 0001193125-26-328422 |
| Document: 0001193125-26-328422.txt | 0001193125-26-328422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 11w ago | Insider Cluster | $27.88 $27.81 | ▼ −0.25% | ▼ −0.85% | $18.95 (−32.03%) |
Aug 3, 2026 12w ago | Insider Buy | $25.71 $26.85 | ▲ +4.43% | ▲ +5.67% | $18.95 (−26.29%) |
Jul 31, 2026 12w ago | 424B4 | $25.00 $26.25 | ▲ +5.00% | ▲ +3.76% | $18.95 (−24.20%) |
Jul 31, 2026 12w ago | EFFECT | $25.00 $29.71 | ▲ +18.84% | ▲ +15.85% | $18.95 (−24.20%) |
Jul 30, 2026 12w ago | 3 | $25.00 $29.71 | ▲ +18.84% | ▲ +15.85% | $18.95 (−24.20%) |
Jul 27, 2026 13w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers